Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | CEL | P19835 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11023325 | 0.91 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL80082 | 0.91 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL11019093 | 0.91 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL11021457 | 0.91 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| Bromide SCHEMBL19330051 | 0.88 | CYP1A2 (0.54) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL3691804 | 0.88 | — | — | |
| SCHEMBL79050 | 0.83 | SIGMAR1 (0.56) | CYP1A2SIGMAR1MAPTEPHX1KDM5A | |
| SCHEMBL11154618 | 0.83 | SIGMAR1 (0.56) | CYP1A2SIGMAR1MAPTEPHX1KDM5A | |
| SCHEMBL19922821 | 0.83 | — | — | |
| SCHEMBL281878 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8366963-B2 | Compound having hydrocoumarin skeleton, liquid crystal compostition, and liquid crystal display device | JNC CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, HCN2, HCN1 | CYP1A2 1327/4885SIGMAR1 1634/4885MAPT 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.